Adlai Nortye (ANL)

• Market cap: $59M
• 1 day: 7.38%
• 5 days: 42.86%
• 1 month: 1.91%
• 3 months: -10.61%
• 6 months: -8.05%
• Year to date: -34.43%
• 1 year: -32.2%
• 5 years: -89.33%
• 10 years: -89.33%
• Sector: Healthcare
• Industry: Biotechnology

About: Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Employees: 123